NCT06095388View on ClinicalTrials.gov

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Mucopolysaccharidosis III-A
Interventions
DRUG

JR-441

IV infusion

DRUG

JR-441

IV infusion

DRUG

JR-441

IV infusion

Trial Locations (1)

Unknown

Universitätsklinikum Hamburg-Eppendorf, Hamburg

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY